FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.
What happened
In August 2025, FDA reviewed Bioverse's website at gobioverse.com and found it offered compounded semaglutide and tirzepatide drug products. FDA said claims such as "Same active ingredient as Ozempic and Wegovy" and "The same active ingredient in Mounjaro and Zepbound" falsely imply the compounded products are the same as FDA-approved drugs. FDA cited these claims as misbranding (false or misleading labeling or promotion).
What FDA found
Bioverse's website claims its compounded semaglutide and tirzepatide have the same active ingredient as FDA-approved Ozempic, Wegovy, Mounjaro, and Zepbound, which FDA says falsely implies the products are the same as approved drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA says these false or misleading claims make the compounded semaglutide and tirzepatide products misbranded drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA says introducing or delivering these misbranded products into interstate commerce is prohibited.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA also says receiving, delivering, or offering to deliver misbranded drugs is prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Bioverse to take immediate action, including ceasing the cited misleading claims, and to respond in writing within 15 working days with steps taken, prevention measures, and supporting documents.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies that supply semaglutide or tirzepatide
- marketing teams that compare compounded drugs to FDA-approved brands
This is a summary. Read the original letter on fda.gov.